KR102747530B1 - 백신 t 세포 인핸서 - Google Patents

백신 t 세포 인핸서 Download PDF

Info

Publication number
KR102747530B1
KR102747530B1 KR1020207013171A KR20207013171A KR102747530B1 KR 102747530 B1 KR102747530 B1 KR 102747530B1 KR 1020207013171 A KR1020207013171 A KR 1020207013171A KR 20207013171 A KR20207013171 A KR 20207013171A KR 102747530 B1 KR102747530 B1 KR 102747530B1
Authority
KR
South Korea
Prior art keywords
leu
vector
ser
ala
gln
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207013171A
Other languages
English (en)
Korean (ko)
Other versions
KR20200076696A (ko
Inventor
알프레도 니코시아
엘리사 스카르셀리
안토넬라 폴고리
아르민 람
Original Assignee
노우스콤 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노우스콤 아게 filed Critical 노우스콤 아게
Publication of KR20200076696A publication Critical patent/KR20200076696A/ko
Application granted granted Critical
Publication of KR102747530B1 publication Critical patent/KR102747530B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/461—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from fish
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10371—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
KR1020207013171A 2017-11-03 2018-11-02 백신 t 세포 인핸서 Active KR102747530B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP17200036 2017-11-03
EP17200036.6 2017-11-03
EP17211235.1 2017-12-29
EP17211235 2017-12-29
PCT/EP2018/080027 WO2019086615A1 (en) 2017-11-03 2018-11-02 Vaccine t cell enhancer

Publications (2)

Publication Number Publication Date
KR20200076696A KR20200076696A (ko) 2020-06-29
KR102747530B1 true KR102747530B1 (ko) 2024-12-27

Family

ID=64332267

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207013171A Active KR102747530B1 (ko) 2017-11-03 2018-11-02 백신 t 세포 인핸서

Country Status (12)

Country Link
US (1) US11912743B2 (https=)
EP (1) EP3703744A1 (https=)
JP (2) JP7386537B2 (https=)
KR (1) KR102747530B1 (https=)
CN (1) CN111670046B (https=)
AU (1) AU2018358019B2 (https=)
BR (1) BR112020008308A2 (https=)
CA (1) CA3078692A1 (https=)
IL (1) IL274409B2 (https=)
MX (1) MX2020004552A (https=)
SG (1) SG11202003799RA (https=)
WO (1) WO2019086615A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210081325A (ko) * 2018-10-19 2021-07-01 노우스콤 아게 경골어류 불변 사슬 암 백신
SG11202103243PA (en) * 2018-11-15 2021-04-29 Nouscom Ag Selection of cancer mutations for generation of a personalized cancer vaccine
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
KR20220115569A (ko) 2019-11-18 2022-08-17 얀센 바이오테크 인코포레이티드 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도
EP4135757A1 (en) * 2020-04-13 2023-02-22 Janssen Biotech, Inc. Psma and steap1 vaccines and their uses
US12295997B2 (en) 2020-07-06 2025-05-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
EP4448001A4 (en) * 2021-12-16 2025-12-03 Janssen Biotech Inc PROSTATE CANCER VACCINES AND THEIR USES

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057501A1 (en) 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
US20160304582A1 (en) 2013-12-04 2016-10-20 Isis Innovation Limited Molecular adjuvant

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE449105T1 (de) 2004-01-23 2009-12-15 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
EP2391638B1 (en) 2009-02-02 2018-06-27 GlaxoSmithKline Biologicals SA Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
WO2012141984A1 (en) 2011-04-08 2012-10-18 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
WO2016013672A1 (ja) 2014-07-25 2016-01-28 国立研究開発法人理化学研究所 メモリーインバリアントｎｋｔ細胞マーカー
JP7298926B2 (ja) * 2017-07-12 2023-06-27 ノイスコム アーゲー 癌の治療のためのネオアンチゲンワクチン組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010057501A1 (en) 2008-11-21 2010-05-27 Københavns Universitet (University Of Copenhagen) Priming of an immune response
JP2012509071A (ja) * 2008-11-21 2012-04-19 ケベンハウン ユニバーシテッド（ユニバーシティー オフ コペンハーゲン） 免疫応答のプライミング
US20160304582A1 (en) 2013-12-04 2016-10-20 Isis Innovation Limited Molecular adjuvant

Also Published As

Publication number Publication date
JP7485422B2 (ja) 2024-05-16
RU2020115109A (ru) 2021-12-03
AU2018358019A1 (en) 2020-04-23
CN111670046B (zh) 2024-11-08
US20210363201A1 (en) 2021-11-25
WO2019086615A1 (en) 2019-05-09
AU2018358019B2 (en) 2023-05-11
IL274409B1 (en) 2023-07-01
CN111670046A (zh) 2020-09-15
RU2020115109A3 (https=) 2021-12-03
JP2023089103A (ja) 2023-06-27
KR20200076696A (ko) 2020-06-29
EP3703744A1 (en) 2020-09-09
SG11202003799RA (en) 2020-05-28
US11912743B2 (en) 2024-02-27
BR112020008308A2 (pt) 2020-11-17
JP7386537B2 (ja) 2023-11-27
IL274409B2 (en) 2023-11-01
NZ763337A (en) 2025-02-28
IL274409A (en) 2020-06-30
JP2021502076A (ja) 2021-01-28
MX2020004552A (es) 2020-10-07
CA3078692A1 (en) 2019-05-09

Similar Documents

Publication Publication Date Title
KR102747530B1 (ko) 백신 t 세포 인핸서
US8470560B2 (en) CR-2 binding peptide P28 as molecular adjuvant for DNA vaccines
JP7638526B2 (ja) 硬骨魚類インバリアント鎖癌ワクチン
AU2018300051B2 (en) Neoantigen vaccine composition for treatment of cancer
CN112930394B (zh) 表达ii类主要组织相容性复合物的癌细胞疫苗和用于产生整合免疫应答的使用方法
CN114929264A (zh) 多结构域蛋白疫苗
CA3109541C (en) Teleost invariant chain cancer vaccine
RU2794196C2 (ru) Усилитель t-клеточного ответа на вакцину
RU2808567C2 (ru) Противораковая вакцина с инвариантной цепью из костистых рыб
RU2782261C2 (ru) Вакцинная композиция для лечения рака

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210510

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230730

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20240814

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

AMND Amendment
PX0901 Re-examination

Patent event code: PX09012R01I

Patent event date: 20241112

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20241202

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20241223

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20241224

End annual number: 3

Start annual number: 1

PG1601 Publication of registration